Literature DB >> 19878274

Voriconazole as primary antifungal prophylaxis in patients with neutropenia after hematopoietic stem cell transplantation or chemotherapy for acute myeloid leukemia.

Antonio Torres, Josefina Serrano, Rafael Rojas, Vanesa Martín, Carmen Martín, Salvador Tabares, José R Molina, Manuel Capote, Francisco Martínez, Pedro Gómez, Joaquín Sánchez-García.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19878274     DOI: 10.1111/j.1600-0609.2009.01367.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


× No keyword cloud information.
  5 in total

1.  Voriconazole and its clinical potential in the prophylaxis of systemic fungal infection in patients with hematologic malignancies: a perspective review.

Authors:  Amaya Zabalza; Ana Gorosquieta; Encarnación Pérez Equiza; Eduardo Olavarria
Journal:  Ther Adv Hematol       Date:  2013-06

Review 2.  Foiling fungal disease post hematopoietic cell transplant: review of prophylactic strategies.

Authors:  S M Rubinstein; K A Culos; B Savani; G Satyanarayana
Journal:  Bone Marrow Transplant       Date:  2017-10-23       Impact factor: 5.483

Review 3.  Recommendations for broader coverage antifungal prophylaxis in childhood acute myeloid leukemia: ASH evidence-based review 2011.

Authors:  Maria M Gramatges; Stuart S Winter
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2011

4.  Outcome of Antifungal Combination Therapy for Invasive Mold Infections in Hematological Patients is Independent of the Chosen Combination.

Authors:  Rafael Rojas; José R Molina; Isidro Jarque; Carmen Montes; Josefina Serrano; Jaime Sanz; Juan Besalduch; Enric Carreras; José F Tomas; Luis Madero; Daniel Rubio; Eulogio Conde; Miguel A Sanz; Antonio Torres
Journal:  Mediterr J Hematol Infect Dis       Date:  2012-02-10       Impact factor: 2.576

5.  A strategy for designing voriconazole dosage regimens to prevent invasive pulmonary aspergillosis based on a cellular pharmacokinetics/pharmacodynamics model.

Authors:  Taotao Wang; Tao Zhang; Ti Meng; Ying Li; Lu Chen; Qianting Yang; Haiyan Dong; Jin'e Lei; Limei Chen; Yalin Dong
Journal:  J Transl Med       Date:  2018-06-07       Impact factor: 5.531

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.